News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The CDCCs are strategically positioned in regions identified as high-impact areas
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
iSolveSM information on demand is the result of our focus on customer relationship
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
